In our study, the impact of the FANCD2 mutation on CML progression and drug resistance highlights the relationship between FANCD2 and the progression of CML to the advanced phase [17,35]. Here, FANCD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.